Clinical Trials Directory

Trials / Unknown

UnknownNCT05795283

Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.

Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Patients With Anorexia Nervosa: a Single-center Study.

Status
Unknown
Phase
Study type
Observational
Enrollment
123 (estimated)
Sponsor
Istituto Auxologico Italiano · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

In patients suffering from anorexia nervosa associated with severe major depression, serotonin reuptake inhibitor drugs have shown little efficacy in significantly reducing depressive symptoms. A possible explanation for this poor efficacy could be that people with anorexia nervosa have a deficiency in amino acids such as tryptophan, which is necessary for the production of the neurotransmitter serotonin. Therefore, tryptophan supplementation has been suggested as a means of increasing the pharmacological response to serotonin reuptake inhibitor drugs in patients with anorexia nervosa. Furthermore, malnutrition present in patients suffering from anorexia nervosa is in some cases associated with problems of intestinal absorption of nutrients, with possible implications on the pharmacokinetics of the drugs administered, including selective serotonin reuptake inhibitors (SSRIs). The present observational study aims to evaluate the correlations between the clinical response to Citalopram therapy (in different o.s. and i.v. formulations) and some nutritional, neurotransmitter and inflammatory biomarkers, in order to identify potential predictive markers of response to therapy for severe major depression in patients with anorexia nervosa. The following parameters will be evaluated in patients enrolled in all 3 observation times described above: * Plasma concentration of Citalopram * Serum concentration of Serotonin * Plasma concentration of dopamine * Serum concentration of Tryptophan * Serum concentration of BDNF * Hamilton scale 17 items and other clinical scales (EDI-3, SCL-90, BUT).

Conditions

Interventions

TypeNameDescription
DRUGCitalopram i.v. and p.oCitalopram: i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28
DRUGCitalopram p.oCitalopram: p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28

Timeline

Start date
2022-08-01
Primary completion
2024-08-01
Completion
2024-08-01
First posted
2023-04-03
Last updated
2023-04-03

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05795283. Inclusion in this directory is not an endorsement.